Jeff Wade is the chairman of the board of BioHouston and an experienced, innovative and entrepreneurial biopharma executive with expertise in setting strategic direction, raising capital, and leveraging strategic partnerships to drive competitive advantage and growth. He served in a range of senior leadership roles at Lexicon Pharmaceuticals (Nasdaq: LXRX), most recently as president and chief operating officer, taking the company from start-up through commercialization of two internally-discovered drugs with a strong pipeline. During his tenure at Lexicon, he was responsible for securing over $1B in equity capital; establishing high-value strategic alliances with industry leaders including Bristol-Myers Squibb, Sanofi and Genentech; overseeing key product launches, bringing Xermelo (telotristat ethyl) and Inpefa (sotagliflozin) to market; and building the company’s therapeutic portfolio.
Before joining Lexicon, Mr. Wade was a partner with the law firm of Andrews & Kurth, where his practice consisted primarily of corporate finance and securities transactions, mergers and acquisitions, and partnerships and alliances. In addition to BioHouston, he is a member of the board of directors of the Texas Healthcare and Bioscience Institute. Mr. Wade received his B.A. (Plan II) and J.D. from The University of Texas.
